Podcasts about focus on cancer

Content Managed by ContentSafe.coSTARTS AT 9PM ET: Join me for an important discussion with Dr. Peter McCullough. To learn more about investing in gold visit - http://goldwithseth.com, or call 720-605-3900 For high quality storable foods and seeds, visit http://heavensharvest.com and use promo code SETH to save 15% on your order. Save up to 66% at https://MyPillow.com using Promo Code - MAN LISTEN VIA PODCAST:Apple: https://apple.co/3bEdO1SSpotify: https://spoti.fi/3u9k8VdPodbean: https://bit.ly/3A4JasyiHeart: https://bit.ly/3npOBea FOLLOW AND WATCH:Website: https://maninamerica.com/Telegram: https://t.me/maninamericaTruth Social: https://truthsocial.com/@maninamericaBanned.Video: https://banned.video/channel/man-in-americaRumble: https://rumble.com/c/ManInAmericaYouTube: https://www.youtube.com/c/maninamericaGab: https://gab.com/ManInAmericaFacebook: https://www.facebook.com/ManInAmericaGettr: https://gettr.com/user/maninamericaTwitter: https://twitter.com/ManInAmericaUSParler: https://parler.com/user/ManInAmericaSafeChat: https://safechat.com/channel/2776713240786468864Tik Tok: https://www.tiktok.com/@maninamerica2Instagram: https://www.instagram.com/maninamericausSee omnystudio.com/listener for privacy information.

Today Ian welcomes Cathy Skinner to the Conscious Podcast. Cathy starts off with a origin story and what motivated her to research and focus on cancer. Cathy then explains her thinking on an example and how her product can monitor and diagnose the patient much more efficiently. She also talks about the advantage of providing a better treatment overall. Cathy also explains the contribution of the product towards camera research. Cathy then talks more about the future with the company and then ends the podcast with some final thoughts for the audience. Parts: 0:00 – Guest Intro 3:21 – Faster Diagnosis 7:19- Better Treatment 13:43 – Subscribe! 14:08 – Research 18:23 – New Fields 21:38 – Guest Outro About Cathy Skinner: Cathy is passionate about growing Healthcare Organizations through innovative programs and services from ideation to commercialization. She has launched three companies that provide products and services for cancer patients and their loved ones. She move companies from ideation to commercialization by bringing together top talent and subject matter experts to build differentiated patient experiences. Know more about Cathy and NxGen Port here: https://www.linkedin.com/in/cathyskinner https://www.nxgenport.com/ ///////// Download chapter 1 free: https://www.petermanfirm.com/conscious-design-chapter-1-free-download/ ///////// Want to be a guest? Visit: https://bit.ly/3BetCkf ///////// Want to work with us?

With Nigel Watson, Wessex Cancer Alliance Board Member and Primary Care Representative Matthew Hayes, Medical Director of Wessex Cancer Alliance and Urological Surgeon at UHS Richard Roope, Sessional GP and Primary Care Advisor for Cancer Research UK and the Wessex Cancer Alliance. Find out more here: https://wessexcanceralliance.nhs.uk/

Matthew Zachary was just 21 years old when he was diagnosed with brain cancer. That was back in 1995, making him a 25-year survivor.  He is the founder of https://offscrip.com/ (OffScrip Media), the first audio broadcast network focused on consumer health and patient advocacy.  You may have heard of a little organization called https://stupidcancer.org/ (Stupid Cancer)...  Well, Matthew is the founder. Under his leadership from 2007 through 2018, Stupid Cancer grew into a powerhouse, as the largest and most influential young adult cancer organization in the world. Matthew is not even close to being done in his mission to call out the bullshit in #cancerland, hold the powerful accountable, and make cancer suck less for the rest of us.

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

More and more people are diagnosed with cancer every day, including children. The rates of invasive cancer in the general population in the U.S. (and abroad) are alarming. Those who are diagnosed with it are faced with conventional treatments that seem to ravage the parts of the body that should be relatively healthy. In today's episode, we focus on nutritional supports for those in the throes of cancer. And for those who are healthy today but want to avoid the disease down the line, we discuss foods that may help keep it at bay. In this "fall journal highlights" episode, Sally Fallon Morell, the president of the Weston A. Price Foundation touches on the numerous factors that are damaging our bodies, including 5G technology. She also explores cancer support for children, homeopathy, and even GcMAF, a controversial, anti-cancer food.  For episode highlights, visit our website westonaprice.org and click on the podcast page. Look for the show notes for episode #107. You will also find links to the articles mentioned in today's episode.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer. But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well. Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations. Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.

Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations. Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.

Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations. Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.

Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations. Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017

Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors. They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways to include complementary therapies in patient treatments.

Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors. They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways to include complementary therapies in patient treatments.

Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors. They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways to include complementary therapies in patient treatments.

Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors. They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways to include complementary therapies in patient treatments.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

[Read the Article] Glioblastoma is the most devastating form of brain cancer in adults; most patients die within one to two years of diagnosis. A new study examined whether using tumor-treating fields, a type of electromagnetic therapy, combined with maintenance chemotherapy in patients with glioblastoma who had already completed standard chemotherapy and radiation, could increase survival.Researchers from University Hospital in Zurich, Switzerland are conducting a worldwide trial with 695 glioblastoma patients. One out of three received a standard maintenance course of chemotherapy, while the other two received maintenance therapy plus the tumor treating fields for up to two years.The current results are for the first 315 patients. Researchers found that use of the tumor-treating fields increased both progression-free survival and overall survival. Overall survival is prolonged by an average of three months in patients getting the tumor-treating fields therapy. [Watch more videos of The JAMA Report]